Aprepitant blocks the brain receptor that substance P prefers, and it reaches the brain to do it. It is a proven nausea drug. It is not a depression drug, and the story of why not is a lesson worth knowing.
Part 15 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Substance P is a small protein-like nerve signal made throughout the body: sensory nerves, the spinal cord, the brainstem, gut nerves, immune cells, and several brain regions all release it.
- Substance P prefers a receptor called NK1. Drugs that block NK1, including aprepitant, are proven, FDA-approved medicines for certain kinds of nausea and vomiting.
- An early depression trial with an NK1 blocker looked promising. Five later, larger phase 3 aprepitant trials for depression did not show benefit. Trials of a related drug, casopitant, had mixed results. No NK1 blocker is approved for any mental health condition.
- A brain scan can show that a drug is sitting on nearly all of a receptor. That is called occupancy. Occupancy proves the drug reached its target. It does not prove the drug helps the illness.
- No blood test, urine test, spinal fluid test, or brain scan can diagnose a person’s substance P level or choose a medicine.
The short answer
Substance P is a short chain of 11 amino acids, which makes it a neuropeptide, the term for a small protein-like signal nerve cells use to communicate. It belongs to a family of related signals called tachykinins. Sensory nerves release it, and so do cells in the spinal cord, the brainstem, the gut’s nervous system, immune-related cells, and several brain regions.
Substance P mainly acts through a receptor called NK1, though two related receptors, NK2 and NK3, respond more strongly to its close chemical cousins. These are preferences, not strict rules. Through NK1, substance P plays a role in nausea and vomiting, pain, swelling caused by nerve activity, the body’s alarm response, and stress-related circuits. More substance P is not automatically bad, and less is not automatically good. What matters is which tissue, which receptor, which nearby signals, and what timing.
This is where the medicine story gets interesting. A class of drugs called NK1 blockers, including aprepitant, directly and reliably prevents certain kinds of nausea and vomiting, especially the delayed nausea that can follow chemotherapy. Aprepitant also crosses into the brain and occupies a large share of NK1 receptors there. Since substance P and NK1 are active in stress and mood-related brain circuits, researchers reasoned that blocking NK1 in the brain might treat depression too. It was a well-founded, testable idea. It did not work.
Substance P’s clearest, best-established job is in the brainstem network that controls vomiting. NK1 blockers can meaningfully cut delayed nausea and vomiting when used as part of a treatment plan, and this remains the one place where blocking this receptor is a proven medical treatment.
Substance P also plays a role in pain. Sensory nerves can release it in the spinal cord and in body tissues, where it adds to pain and swelling signals in some situations. But pain is never just one chemical. It is shaped by tissue injury, nerve activity, immune signals, sleep, mood, past experience, and context all at once, so substance P activity cannot be read off of how much pain someone reports.
Outside the nervous system, substance P released from sensory nerves can widen blood vessels and contribute to local inflammation. How much this matters depends heavily on the specific tissue and condition involved, and it cannot be guessed from symptoms like anxiety, flushing, or pain alone.
The stress and mood story is the most complicated one, and it is the heart of this article. Animal research linked blocking NK1 with reduced stress responses and fewer depression-like behaviors. That research was solid enough to justify testing the idea in people. The human treatment program, described below, did not hold up.
Meet the tachykinin receptors
Substance P belongs to a family of related signals, and each one prefers a different receptor, though the preferences overlap.1
| Receptor | What it does, where it matters most, and why you might care |
|---|---|
| NK1 | What it does: Turns on a calcium-based signal inside the receiving cell. Where it matters most: The brainstem’s vomiting-control network, sensory and spinal pain pathways, mood-related circuits, the gut, and other body tissues. Why you might care: The proven target for antiemetic drugs like aprepitant. Also the target that failed as a depression treatment despite reaching the brain. |
| NK2 | What it does: A similar calcium-based signal; prefers a related peptide called neurokinin A more than substance P. Where it matters most: Gut, smooth muscle, and some brain sites. Why you might care: Rounds out the family. No medicine in routine mental health use targets it directly. |
| NK3 | What it does: A similar calcium-based signal; prefers a related peptide called neurokinin B more than substance P. Where it matters most: Hypothalamus, hormone-regulating circuits, and some brain sites. Why you might care: Plays a real hormone-related role, but is not a substance-P-specific treatment target. |
Occupancy is not benefit
A brain scan called PET can estimate how much of a drug’s target receptor is occupied, meaning the share of available receptors the drug is actually sitting on under set conditions. A study using this technique showed that rolapitant, another NK1 blocker, could enter the human brain and occupy a large share of the available NK1 receptors there.
That result proves the drug reaches its target. It does not prove the drug helps depression, or any other condition, once it gets there. Whatever happens after a drug occupies a receptor, at the level of the whole brain circuit and then the whole person, is a separate question that an occupancy scan cannot answer by itself.
This distinction is exactly what the depression research ran into.
Why the depression trials failed
An early NK1-blocker depression trial in 1998 looked positive, and it was reasonable to expect the finding to hold up in larger studies.2 It did not. A later report covering five separate phase 3 aprepitant trials for depression found no clear benefit across them.3 A related drug, casopitant, was tested in two more depression trials, and results were mixed rather than clearly positive.4
No NK1 blocker has ever been approved for depression or any other mental health condition. The receptor action itself was real and confirmed. Aprepitant does reach NK1, and it does block it. What did not follow was a reliable mental health benefit in the trials designed to detect one.
This is the core lesson of the whole article: a drug reaching its intended target, even reaching it strongly and reliably, is only the first step. Whatever happens across a mood circuit, and then across a person’s actual symptoms over weeks, is governed by more than which receptor the drug sits on.
None of this erases what NK1 blockers do well. Aprepitant, fosaprepitant, and rolapitant remain genuinely useful antiemetic drugs.567 Fosaprepitant is given by IV and converts into aprepitant in the body.68 Rolapitant is a longer-acting oral option with an active breakdown product called M19 that keeps working for days after the dose.7 These are real, FDA-approved medicines for nausea and vomiting. They have simply never earned an approval for depression, because the trials that tested that specific claim did not support it.
An important interaction to know
Aprepitant changes how the liver processes certain other drugs, and this matters beyond the nausea-treatment setting. Aprepitant is contraindicated with pimozide, meaning the two should never be combined.5
Oral rolapitant carries a related but distinct warning. It is contraindicated with narrow-therapeutic-index drugs broken down by a liver enzyme called CYP2D6, including pimozide and thioridazine.7 A narrow-therapeutic-index drug is one where the gap between an effective dose and a harmful one is small, so even a modest change in blood level from a drug interaction can matter. Rolapitant’s effect on CYP2D6 is unusually long-lasting: it can continue to affect how the body processes those drugs for at least 28 days after the last rolapitant dose, well past when most people would assume the interaction risk was over.7
Can substance P be measured?
Not in a way that is useful for diagnosing or treating a mental health condition.
Blood or plasma tests can detect substance P, but the result is shaped by platelets, nearby nerve activity, inflammation, how the sample was handled, and the specific test method used. It is a body-wide measurement, not a brain-circuit one.
Spinal fluid sits closer to the central nervous system, but it still combines signals from many different sources and cannot identify what is happening at one specific connection between nerve cells.
PET scans with the right tracer can estimate how much free NK1 receptor is available in the brain, or how much a drug occupies. This is a research and drug-development tool. It is not a routine test for depression or anxiety, and it is not used to choose a person’s medicine.
Tissue examined after death can map where peptides and receptors were located, but the cause of death, the dying process itself, medicines, other substances, and delays in sampling can all change the result.
No routine blood, urine, saliva, spinal fluid, brain scan, or gene test can diagnose a person’s substance P state or select an NK1-targeting medicine.
What each medicine actually touches
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Aprepitant | What it does directly: Directly blocks NK1. Used for: Preventing certain kinds of nausea and vomiting, often as part of a larger drug plan. Main tradeoffs: Changes how the liver processes other drugs through two enzymes, CYP3A4 and CYP2C9; contraindicated with pimozide. |
| Fosaprepitant | What it does directly: Given by IV; converts into aprepitant in the body. Used for: The same nausea-prevention uses as aprepitant, when an IV option is needed. Main tradeoffs: Can cause severe allergic reactions and infusion-site reactions; drug-interaction risks vary by product. |
| Rolapitant (oral) | What it does directly: A long-acting NK1 blocker; its active breakdown product, M19, keeps working for days. Used for: Preventing delayed nausea and vomiting in adults. Main tradeoffs: CYP2D6 inhibition can last at least 28 days after the last dose; contraindicated with narrow-therapeutic-index CYP2D6 drugs including pimozide and thioridazine. |
| Aprepitant and casopitant, in past depression research | What it does directly: NK1 blockade, the same action used for nausea. Used for: Tested for major depression; never approved for it. Main tradeoffs: Five phase 3 aprepitant trials showed no clear benefit; casopitant results were mixed. Neither reached approval for a mental health use. |
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: mild nausea, fatigue, headache, appetite changes, mood changes, pain, or sleep changes, along with when they started and your full list of medicines.
Call the prescriber or pharmacist promptly: vomiting that will not stop, an inability to keep other medicines down, a new rash, a hard-to-manage reaction at an infusion site, a major mood or behavior change, or any concern about a drug interaction. Do not try to fix a suspected drug interaction on your own. Aprepitant is contraindicated with pimozide. Oral rolapitant is contraindicated with narrow-therapeutic-index CYP2D6 drugs including pimozide and thioridazine.
Call Poison Control at 1-800-222-1222 for a suspected overdose or medicine mix-up without life-threatening symptoms. Do not wait for symptoms to appear before calling.
Call 911 now for breathing difficulty, swelling of the face or throat, collapse, seizure, inability to wake someone, severe confusion, or severe chest or heart symptoms. For a suicidal or mental health crisis, call or text 988. A call to Poison Control or a routine prescriber call should never delay a 911 call in an emergency.
What to ask your prescriber
These are conversation starters, not instructions.
- What symptom, whether nausea, pain, or mood, is this medicine actually meant to target?
- What does it bind directly, and which effects come later, downstream of that?
- What improvement should we look for first, and by when?
- Which effects are likely to settle on their own, and which need a prompt call?
- Could this medicine change the levels of my other medicines, including mental health medicines?
- Does this drug interact with pimozide, warfarin, birth control, steroids, supplements, alcohol, or cannabis?
- What monitoring makes sense for this specific product and for me?
- What should I do if I miss a dose?
- Could stopping another medicine in my regimen suddenly cause withdrawal or rebound symptoms?
Bottom line
Aprepitant reaches the brain and blocks NK1 as reliably as any drug reaches any target. It still is not a depression medicine, because five phase 3 trials designed to test exactly that claim came back negative.3 Your brain is not a gas tank, and hitting a target in it is not the same as fixing what is wrong. The same gap between a confirmed mechanism and confirmed benefit shows up in cholecystokinin research, where a drug reliably blocked its receptor and still failed as a panic treatment. What NK1 blockers do reliably is prevent certain kinds of nausea and vomiting, and that alone makes them valuable medicines. Ask what a drug actually touches, what tradeoffs come with it, and what would count as evidence that it is working for you specifically.
Frequently asked questions
Does depression or chronic stress mean I have too much substance P?
No. These symptoms are not specific to substance P, and the trials that directly tested an NK1 blocker for depression did not confirm any simple excess model.
If aprepitant reaches the brain, why doesn’t it treat depression?
Reaching and sitting on NK1 is only the first step. What happens next, across a mood circuit and then across a person’s actual symptoms, has to follow, and in five phase 3 trials it did not.3
Is substance P only involved in pain?
No. It also plays a role in nausea, the body’s alarm response, immune signaling, and stress circuits.
Can a blood test help choose an NK1 medicine for me?
No. A body-wide substance P level cannot show what is happening at a receptor in a living brain circuit, and it has no proven use for choosing a medicine.
Why are NK1 nausea drugs often combined with other medicines?
Nausea and vomiting involve more than one biological signal, so treatment plans often combine drugs that work through different targets. Only a clinician or pharmacist should manage that combination.
Are all NK1 blockers interchangeable?
No. They differ in how long they last, their active breakdown products, which liver enzymes they affect, age approvals, and how they are given.
Does a side effect from an NK1 nausea drug mean it is working?
No. A side effect can come from NK1 itself, from another receptor the drug touches, from a change in the levels of another medicine, or from the underlying illness.
Can stopping a short course of an NK1 nausea drug cause withdrawal?
There is no known substance-P withdrawal syndrome tied to these drugs. Follow your prescription as directed and tell your prescriber about any new symptoms.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- The Gut Signal That Can Trigger Panic in a Lab
- Your Body Makes Its Own Opioids
- The Waiting Game: Why Antidepressants Take Time and How to Make Those First 6 Weeks Count
References
1. IUPHAR/BPS tachykinin receptor record. Guide to Pharmacology. Accessed August 31, 2026. https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=62
2. Early NK1-blocker depression trial, 1998. https://doi.org/10.1126/science.281.5383.1640
3. Report of five later phase 3 aprepitant depression trials. https://doi.org/10.1016/j.biopsych.2005.07.013
4. Casopitant depression trials. https://doi.org/10.1097/JCP.0b013e31823608ca
5. Aprepitant prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a
6. Fosaprepitant prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9dbd4c29-d894-4839-9b22-a2f65c8c8ad1
7. Oral rolapitant (VARUBI) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a52896cd-4a98-49b8-82db-bf1985a64d97
8. FDA review of a newer fosaprepitant injection formulation, NDA 216686. U.S. Food and Drug Administration. Accessed August 31, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216686Orig1s000MultidisciplineR.pdf
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, or change a medicine because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.